Workspaces
Log in Sign up

Amgen's Tavneos Faces Regulatory Collapse Following NEJM Retraction and FDA Withdrawal Proposal

Updated

Sources

Amgen's Tavneos Faces Regulatory Collapse Following NEJM Retraction and FDA Withdrawal Proposal

The global regulatory and scientific integrity crisis surrounding Amgen’s rare kidney disease drug Tavneos (avacopan) has reached a critical milestone. On August 6, 2026, the European Commission officially revoked the marketing authorization for Tavneos across all European Union member states and the European Economic Area. This final action codifies the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) June 25, 2026, recommendation to revoke the drug's approval due to severe Good Clinical Practice (GCP) and data-integrity violations1 in its sole pivotal trial, ADVOCATE.

EMA Details Post-Unblinding Database Modification

The EMA's Article 20 Public Assessment Report, published on August 6, 2026, provides a step-by-step regulatory account of the data manipulation. Investigators confirmed that nine patient records in the ADVOCATE trial database were altered after the database was officially sealed and treatment assignments were unblinded in November 2019. These post-unblinding modifications directly erased the comparator arm's efficacy and manufactured the statistical superiority claim required for avacopan's regulatory approvals.

The FDA's investigation identified two former ChemoCentryx employees (the original developer acquired by Amgen for $3.7 billion in 2022) who had access to the unblinded data and were involved in modifying the database:

  • Huibin Yue, PhD: Director of Biostatistics.
  • Pirow Bekker, MD, PhD: Chief Medical Officer and co-author of the original ADVOCATE study paper.

The database manipulation led The New England Journal of Medicine (NEJM) to formally retract the pivotal ADVOCATE trial paper on June 29, 2026, citing conduct "inconsistent with proper research conduct."

Parallel FDA Safety Warning

In addition to the data integrity failure, a parallel clinical safety signal has heavily weighted against the drug. In a March 31, 2026, drug safety communication, the FDA identified 76 cases of serious drug-induced liver injury (DILI) causally associated with avacopan, resulting in 54 hospitalizations and 8 patient deaths globally.

Amgen Contests U.S. Market Withdrawal

While Tavneos has been completely removed from the European market, it remains commercially available in the United States. Amgen is actively fighting the FDA's April 27, 2026, proposal to withdraw the drug's U.S. approval. On July 23, 2026, Amgen formally submitted a comprehensive data and analysis package to the FDA, requesting a formal public hearing. The submission includes a third-party re-adjudication of the ADVOCATE data, real-world evidence from 71 studies involving over 2,200 patients, and post-marketing safety data.

However, the EMA's CHMP reviewed similar arguments and concluded that a retrospective re-analysis cannot repair a fundamental Good Clinical Practice violation, setting a daunting precedent for Amgen's upcoming U.S. hearing.

"When regulators at the European Medicines Agency published the full scientific rationale behind Europe's withdrawal of avacopan on August 6, 2026, they put on record something that clinical trial sponsors and drug regulators worldwide will be studying for years: a step-by-step account of how nine altered patient records — changed after a trial's database was sealed and treatment assignments were revealed — can destroy the evidentiary foundation of a $459 million drug approval." — Tech Times Article

"The European Commission has officially revoked the marketing authorization for Tavneos (avacopan), finalizing a process that began with regulators flagging the drug's pivotal trial data as 'incorrect and misleading.' ... The action mirrors a parallel U.S. proceeding, where the FDA proposed withdrawing Tavneos' approval in April over similar data manipulation concerns." — American Pharmaceutical Review

  1. An instance of Data integrity failures trigger a global regulatory crackdown on clinical trial validity. — Regulatory agencies revoked marketing authorizations globally following the exposure of post-unblinding database manipulation in the drug's sole trial. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Backlinks

Revision history

  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent